PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
December 11, 2019New England Journal of MedicineOpen Access

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

RMRashmi K. MurthySLSherene LoiAOAlicia Okines

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Murthy et al. (2019) studied this question.

synapsesocial.com/papers/69dbd56c3d9adb00e7685318https://doi.org/10.1056/nejmoa1914609
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Population-based Estimate of the Prevalence of HER-2 Positive Breast Cancer Tumors for Early Stage Patients in the US2010 · 194 citations
  2. 2A group sequential Holm procedure with multiple primary endpoints2012 · 48 citations
  3. 3Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA2014 · 404 citations